433 related articles for article (PubMed ID: 20198685)
21. Combined flow cytometric assessment of CD45, HLA-DR, CD34, and CD117 expression is a useful approach for reliable quantification of blast cells in myelodysplastic syndromes.
Sandes AF; Kerbauy DM; Matarraz S; Chauffaille Mde L; López A; Orfao A; Yamamoto M
Cytometry B Clin Cytom; 2013 May; 84(3):157-66. PubMed ID: 23475532
[TBL] [Abstract][Full Text] [Related]
22. Immunophenotype of myeloid cells in myelodysplastic syndromes and its clinical implications.
Shao Z; Chen G; Lin Z; Zhang Y; Hao Y; Chu Y; Zheng Y; Qian L; Yang T; Yang C; Feng B
Chin Med J (Engl); 1998 Jan; 111(1):28-31. PubMed ID: 10322648
[TBL] [Abstract][Full Text] [Related]
23. [Abnormalities of CD34+ cells differentiation and bone marrow cell cycle in myelodysplastic syndrome].
Li LJ; Fu R; Shao ZH; Wang HQ; Yue LZ; Ruan EB; Liu H; Wang J; Wang HL
Zhonghua Nei Ke Za Zhi; 2010 Nov; 49(11):963-6. PubMed ID: 21211213
[TBL] [Abstract][Full Text] [Related]
24. Peripheral blood MDS score: a new flow cytometric tool for the diagnosis of myelodysplastic syndromes.
Cherian S; Moore J; Bantly A; Vergilio JA; Klein P; Luger S; Bagg A
Cytometry B Clin Cytom; 2005 Mar; 64(1):9-17. PubMed ID: 15668954
[TBL] [Abstract][Full Text] [Related]
25. Physician Education: Myelodysplastic Syndrome.
Yoshida Y
Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
[TBL] [Abstract][Full Text] [Related]
26. Improving the differential diagnosis between myelodysplastic syndromes and reactive peripheral cytopenias by multiparametric flow cytometry: the role of B-cell precursors.
Reis-Alves SC; Traina F; Metze K; Lorand-Metze I
Diagn Pathol; 2015 Apr; 10():44. PubMed ID: 25924846
[TBL] [Abstract][Full Text] [Related]
27. The value of cell cultures for the diagnosis of mixed myelodysplastic/myeloproliferative disorders.
Del Cañizo MC; Brufau A; Mota A; Lopez N; Fernandez ME; Vallejo C; Hernandez JM; Garcia JL; San Miguel JF
Haematologica; 1998 Jan; 83(1):3-7. PubMed ID: 9580461
[TBL] [Abstract][Full Text] [Related]
28. Detection of molecular targets on the surface of CD34+CD38- bone marrow cells in myelodysplastic syndromes.
Xie W; Wang X; Du W; Liu W; Qin X; Huang S
Cytometry A; 2010 Sep; 77(9):840-8. PubMed ID: 20662087
[TBL] [Abstract][Full Text] [Related]
29. Detection of hematopoietic maturation abnormalities by flow cytometry in myelodysplastic syndromes and its utility for the differential diagnosis with non-clonal disorders.
Lorand-Metze I; Ribeiro E; Lima CS; Batista LS; Metze K
Leuk Res; 2007 Feb; 31(2):147-55. PubMed ID: 16750852
[TBL] [Abstract][Full Text] [Related]
30. Angiogenesis in relation to clinical stage, apoptosis and prognostic score in myelodysplastic syndromes.
Lundberg LG; Hellström-Lindberg E; Kanter-Lewensohn L; Lerner R; Palmblad J
Leuk Res; 2006 Mar; 30(3):247-53. PubMed ID: 16099505
[TBL] [Abstract][Full Text] [Related]
31. [Study on the Characteristics of cell cycle and proliferation of CD34+ hematopoietic stem cells in myelodysplastic syndromes].
Shi J; Shao ZH; Liu H; Jia HR; Sun J; Bai J; Wu YH; Jing LP; He GS; Cao YR; Wang XL; Tu MF; Hao YS; Yang TY
Zhonghua Xue Ye Xue Za Zhi; 2004 Nov; 25(11):641-4. PubMed ID: 15634564
[TBL] [Abstract][Full Text] [Related]
32. Flow cytometric scoring system (FCMSS) assisted diagnosis of myelodysplastic syndromes (MDS) and the biological significance of FCMSS-based immunophenotypes.
Xu F; Li X; Wu L; He Q; Zhang Z; Chang C
Br J Haematol; 2010 May; 149(4):587-97. PubMed ID: 20331463
[TBL] [Abstract][Full Text] [Related]
33. Assessment of stromal function, and its potential contribution to deregulation of hematopoiesis in the myelodysplastic syndromes.
Tauro S; Hepburn MD; Bowen DT; Pippard MJ
Haematologica; 2001 Oct; 86(10):1038-45. PubMed ID: 11602409
[TBL] [Abstract][Full Text] [Related]
34. Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis.
Stifter G; Heiss S; Gastl G; Tzankov A; Stauder R
Eur J Haematol; 2005 Dec; 75(6):485-91. PubMed ID: 16313260
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of CD7 and terminal deoxynucleotidyl transferase (TdT) expression in CD34+ myeloblasts from patients with myelodysplastic syndrome.
Font P; Subirá D; Mtnez-Chamorro C; Castañón S; Arranz E; Ramiro S; Gil-Fernández JJ; López-Pascual J; Alonso A; Pérez-Sáenz MA; Alaez C; Renedo M; Blas C; Escudero A; Fdez-Rañada JM
Leuk Res; 2006 Aug; 30(8):957-63. PubMed ID: 16417922
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic application and clinical significance of FCM progress scoring system based on immunophenotyping in CD34+ blasts in myelodysplastic syndromes.
Xu F; Guo J; Wu LY; He Q; Zhang Z; Chang CK; Li X
Cytometry B Clin Cytom; 2013; 84(4):267-78. PubMed ID: 23554290
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of a Bone Marrow Dysmyelopoiesis Immunophenotypic Index for the Diagnosis and Prognosis of Myelodysplastic Syndromes.
Verigou E; Lampropoulou P; Smyrni N; Kolliopoulou G; Sakellaropoulos G; Starakis I; Zikos P; Solomou E; Symeonidis A; Karakantza M
Cardiovasc Hematol Disord Drug Targets; 2015; 15(2):148-61. PubMed ID: 26126819
[TBL] [Abstract][Full Text] [Related]
38. Clinical implications of immunophenotypic abnormalities of bone marrow myeloid cell compartment in myelodysplastic syndromes.
Marisavljevic D; Kraguljac-Kurtovic N
J BUON; 2010; 15(4):746-52. PubMed ID: 21229640
[TBL] [Abstract][Full Text] [Related]
39. Flow cytometry in myelodysplastic syndrome: analysis of diagnostic utility using maturation pattern-based and quantitative approaches.
Chopra A; Pati H; Mahapatra M; Mishra P; Seth T; Kumar S; Singh S; Pandey S; Kumar R
Ann Hematol; 2012 Sep; 91(9):1351-62. PubMed ID: 22526362
[TBL] [Abstract][Full Text] [Related]
40. A multiparametric flow cytometry immunophenotypic scoring system for the diagnosis and prognosis of myelodysplastic syndromes.
Huang J; Lai P; Zhou M; Weng J; Lu Z; Du X
Clin Lab; 2012; 58(11-12):1241-51. PubMed ID: 23289195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
